MA38583A1 - Dérivés de dolastatine 10 et d'auristatines - Google Patents

Dérivés de dolastatine 10 et d'auristatines

Info

Publication number
MA38583A1
MA38583A1 MA38583A MA38583A MA38583A1 MA 38583 A1 MA38583 A1 MA 38583A1 MA 38583 A MA38583 A MA 38583A MA 38583 A MA38583 A MA 38583A MA 38583 A1 MA38583 A1 MA 38583A1
Authority
MA
Morocco
Prior art keywords
auristatines
dolastatin
derivatives
compound
relates
Prior art date
Application number
MA38583A
Other languages
English (en)
Other versions
MA38583B1 (fr
Inventor
Michel Perez
Ian Rilatt
Marie Lamothe
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA38583A1 publication Critical patent/MA38583A1/fr
Publication of MA38583B1 publication Critical patent/MA38583B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé de formule suivante (i): où : r
MA38583A 2013-04-25 2014-04-25 Dérivés de dolastatine 10 et d'auristatines MA38583B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1353793A FR3005051A1 (fr) 2013-04-25 2013-04-25 Derives de la dolastatine 10 et d'auristatines
PCT/EP2014/058427 WO2014174064A1 (fr) 2013-04-25 2014-04-25 Dérivés de dolastatine 10 et d'auristatines

Publications (2)

Publication Number Publication Date
MA38583A1 true MA38583A1 (fr) 2018-07-31
MA38583B1 MA38583B1 (fr) 2018-11-30

Family

ID=48782433

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38583A MA38583B1 (fr) 2013-04-25 2014-04-25 Dérivés de dolastatine 10 et d'auristatines

Country Status (32)

Country Link
US (7) US20160083420A1 (fr)
EP (4) EP2989086B1 (fr)
JP (3) JP6606489B2 (fr)
KR (4) KR20160003735A (fr)
CN (3) CN105377834B (fr)
AU (3) AU2014259429A1 (fr)
BR (3) BR112015026478A2 (fr)
CA (4) CA2910176C (fr)
CY (2) CY1119677T1 (fr)
DK (3) DK2989086T3 (fr)
ES (3) ES2908224T3 (fr)
FR (1) FR3005051A1 (fr)
HK (1) HK1215580A1 (fr)
HR (2) HRP20171977T1 (fr)
HU (3) HUE040431T2 (fr)
IL (1) IL242184A (fr)
LT (2) LT2989088T (fr)
MA (1) MA38583B1 (fr)
MX (3) MX372911B (fr)
MY (1) MY177702A (fr)
NO (1) NO2989088T3 (fr)
NZ (1) NZ714203A (fr)
PL (3) PL2989086T3 (fr)
PT (2) PT2989088T (fr)
RS (2) RS56717B1 (fr)
RU (3) RU2662951C2 (fr)
SA (1) SA515370043B1 (fr)
SI (2) SI2989086T1 (fr)
TN (2) TN2015000445A1 (fr)
UA (1) UA115806C2 (fr)
WO (3) WO2014174062A1 (fr)
ZA (1) ZA201508545B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
CN106470708B (zh) * 2014-04-25 2019-12-31 皮埃尔法布雷医药公司 抗体-药物-缀合物和其用于治疗癌症的用途
EP3134124B1 (fr) 2014-04-25 2019-02-20 Pierre Fabre Medicament Conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer
EP3160513B1 (fr) 2014-06-30 2020-02-12 Glykos Finland Oy Dérivé de saccharide d'une charge utile toxique et conjugués d'anticorps de celui-ci
EP3954394A1 (fr) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Systèmes d'administration pour la libération contrôlée de médicaments
JP2019510000A (ja) * 2016-02-26 2019-04-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． 新規トキシン及びその中間体の製造方法
WO2017170637A1 (fr) * 2016-03-29 2017-10-05 東レ株式会社 Dérivé peptidique et son utilisation
CN105968038A (zh) * 2016-05-09 2016-09-28 湖北华世通生物医药科技有限公司 二肽类化合物的盐酸盐及其制备方法
CN106432318A (zh) * 2016-08-18 2017-02-22 重庆大学 一种芳炔前体的设计，合成，及在合成多取代芳烃的应用
CN107325033A (zh) * 2017-06-23 2017-11-07 华东师范大学 一种高立体选择性合成海兔毒素Dap片段的方法
DK3717503T3 (da) * 2017-11-30 2024-01-22 Ladrx Corp Albumin-bindende prodrugs af auristatin E derivater
AU2019350536B2 (en) 2018-09-27 2026-04-23 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
CN110724337B (zh) * 2019-10-16 2022-04-05 江苏德威新材料股份有限公司 一种硅烷交联型阻燃半导电聚烯烃护套材料及其制备方法和应用
EP4400121A1 (fr) 2021-09-03 2024-07-17 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prévention du cancer
WO2024213080A1 (fr) 2023-04-12 2024-10-17 荣昌生物制药(烟台)股份有限公司 Préparation et procédé de purification d'un composé de monométhyl auristatine e
WO2024245227A1 (fr) * 2023-06-02 2024-12-05 荣昌生物制药(烟台)股份有限公司 Procédé de préparation et de purification d'un intermédiaire de composé de méthyl auristatine e
CN118165066B (zh) * 2024-02-26 2025-03-21 复旦大学 一种含氟多肽及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3469580B2 (ja) * 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP5171621B2 (ja) * 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
KR101674097B1 (ko) * 2008-04-11 2016-11-08 시애틀 지네틱스, 인크. 췌장, 난소 및 다른 암의 검출 및 치료
CA2754531A1 (fr) * 2009-03-06 2010-09-30 Seattle Genetics, Inc. Conjugues anticorps-medicament (adc) se liant aux proteines 24p4c12
CA2801971C (fr) * 2010-06-10 2018-07-24 Hans-Georg Lerchen Nouveaux derives de l'auristatine et leur utilisation
ES2553874T3 (es) * 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
CA2930801C (fr) * 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Conjugues de polypeptides obtenus par genie biologique, et procede de fabrication correspondants au moyen de transglutaminase
CA2829736C (fr) * 2011-03-16 2020-07-21 Seattle Genetics, Inc. N-carboxyalkylauristatines et leur utilisation
EP3501546A3 (fr) * 2011-04-21 2019-09-18 Seattle Genetics, Inc. Nouveaux conjugués cystéine-principe actif et leur utilisation
EP2714685B1 (fr) * 2011-05-27 2016-10-19 Ambrx, Inc. Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel
CN103717595A (zh) * 2011-05-27 2014-04-09 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
MX363116B (es) * 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
EP4406612A3 (fr) * 2012-06-19 2024-10-16 Ambrx, Inc. Conjugués anticorps-médicament anti-cd70
US20150314007A1 (en) * 2012-12-21 2015-11-05 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
CN106470708B (zh) * 2014-04-25 2019-12-31 皮埃尔法布雷医药公司 抗体-药物-缀合物和其用于治疗癌症的用途

Also Published As

Publication number Publication date
US20160068567A1 (en) 2016-03-10
CN105143199A (zh) 2015-12-09
MY177702A (en) 2020-09-23
ES2654364T3 (es) 2018-02-13
CY1120863T1 (el) 2019-12-11
RS58161B1 (sr) 2019-03-29
WO2014174060A1 (fr) 2014-10-30
JP6606489B2 (ja) 2019-11-13
PT2989086T (pt) 2018-11-29
BR112015026410A2 (pt) 2017-07-25
US20180222858A1 (en) 2018-08-09
PT2989088T (pt) 2018-01-03
ES2693368T3 (es) 2018-12-11
BR112015026565A2 (pt) 2017-07-25
DK3388427T3 (da) 2022-03-07
AU2014259427A1 (en) 2015-11-19
EP2989087A1 (fr) 2016-03-02
SI2989086T1 (sl) 2018-12-31
PL2989086T3 (pl) 2019-02-28
MX372911B (es) 2020-04-27
EP2989086B1 (fr) 2018-08-22
MX2015014831A (es) 2016-08-03
ZA201508545B (en) 2017-07-26
JP2016519114A (ja) 2016-06-30
UA115806C2 (uk) 2017-12-26
FR3005051A1 (fr) 2014-10-31
JP6017728B2 (ja) 2016-11-02
KR20160003735A (ko) 2016-01-11
RS56717B1 (sr) 2018-03-30
MX2015014941A (es) 2016-03-07
JP2016519115A (ja) 2016-06-30
KR102368136B1 (ko) 2022-02-25
US20160068566A1 (en) 2016-03-10
CY1119677T1 (el) 2018-04-04
HUE058167T2 (hu) 2022-07-28
RU2015149527A (ru) 2017-05-29
RU2015147447A (ru) 2017-05-31
TN2015000439A1 (en) 2017-01-03
SA515370043B1 (ar) 2018-01-24
LT2989088T (lt) 2018-01-10
AU2014259431A1 (en) 2015-12-03
HK1215580A1 (zh) 2016-09-02
CA3130994A1 (fr) 2014-10-30
DK2989088T3 (en) 2017-12-18
US20200010414A1 (en) 2020-01-09
WO2014174064A1 (fr) 2014-10-30
CN105377834A (zh) 2016-03-02
HUE040431T2 (hu) 2019-03-28
KR101640361B1 (ko) 2016-07-15
TN2015000445A1 (en) 2017-04-06
EP2989088A1 (fr) 2016-03-02
MX345126B (es) 2017-01-17
CA2910176A1 (fr) 2014-10-30
LT2989086T (lt) 2018-11-26
EP3388427A1 (fr) 2018-10-17
EP3388427B1 (fr) 2022-01-19
EP2989086A1 (fr) 2016-03-02
KR20160003734A (ko) 2016-01-11
HK1215867A1 (zh) 2016-09-23
AU2014259431B2 (en) 2017-02-02
KR102389167B1 (ko) 2022-04-20
US20210107868A1 (en) 2021-04-15
PL2989088T3 (pl) 2018-03-30
BR112015026478A2 (pt) 2017-07-25
AU2014259427B2 (en) 2018-04-05
HRP20181890T1 (hr) 2019-01-11
ES2908224T3 (es) 2022-04-28
RU2015146957A (ru) 2017-05-31
WO2014174062A1 (fr) 2014-10-30
CA2910178A1 (fr) 2014-10-30
MX2015014746A (es) 2016-03-04
SI2989088T1 (en) 2018-02-28
EP2989088B1 (fr) 2017-09-27
CN105377834B (zh) 2018-04-20
AU2014259429A1 (en) 2015-11-12
DK2989086T3 (en) 2018-11-12
IL242184A (en) 2017-09-28
JP2016520041A (ja) 2016-07-11
MA38583B1 (fr) 2018-11-30
NO2989088T3 (fr) 2018-02-24
HUE035180T2 (hu) 2018-05-02
CA2909126A1 (fr) 2014-10-30
RU2662951C2 (ru) 2018-07-31
NZ714203A (en) 2020-05-29
US20230002316A1 (en) 2023-01-05
KR20210046871A (ko) 2021-04-28
PL3388427T3 (pl) 2022-05-09
CA2910176C (fr) 2021-11-09
HRP20171977T1 (hr) 2018-02-09
US20160083420A1 (en) 2016-03-24
KR20160003003A (ko) 2016-01-08
BR112015026410B1 (pt) 2022-06-07
CN105408318A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
MA38583B1 (fr) Dérivés de dolastatine 10 et d&#39;auristatines
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
BR112013002182A2 (pt) derivados de quinolina e inibidores de melk contendo os mesmos
MY180083A (en) Tetrahydropyrrolothiazine compounds
MA38050A1 (fr) Inhibiteurs de gdf-8
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201690911A1 (ru) Соединения диметилбензойной кислоты
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MA38404A1 (fr) Nouveaux dérivés de pyridine
EA201690894A1 (ru) Феноксиэтилы
EA201592183A1 (ru) Ингибиторы bace
MA37686B1 (fr) Composés phénoxyéthyl pipéridine
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
MA37650A1 (fr) Forme amorphe d&#39;un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
JOP20200030B1 (ar) مركب خماسي الحلقة
JOP20170164A1 (ar) مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EA201690924A1 (ru) Фторфенилпиразольные соединения
CR20140114A (es) Compuestos de benzotiazolona
MA20150280A2 (fr) Dérivés d&#39;aryléthynyle
EA201690593A1 (ru) Новые соединения мочевины
EA201400269A1 (ru) Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина
CR20130029A (es) Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos